BioCentury | Jun 1, 2020
Product Development

Ibrance failure in adjuvant breast cancer opens door for Novartis, Lilly

The failure of Pfizer’s second-best-selling drug Ibrance in a pivotal trial as an adjuvant treatment for breast cancer opens a window for rival drugs in an indication that could have been a major growth opportunity...
BC Extra | Jan 28, 2020
Company News

Bourla chooses BD over buybacks in 2020

CEO Albert Bourla outlined his vision for the new innovative business that will emerge from Pfizer after the spin-off of Upjohn, saying that the company would invest in business development and pipeline growth rather than...
BC Extra | Jan 2, 2020
Politics & Policy

Drug price hikes would have been impossible under pending bipartisan legislation backed by White House, Democrats

The latest round of increases in the list prices of drugs highlights how pending bipartisan legislation could force biopharma companies to rethink their business models. In what has become a predictable biannual event, manufacturers announced...
BC Innovations | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BC Extra | Nov 22, 2019
Financial News

Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into...
BC Innovations | Nov 18, 2019
Distillery Therapeutics

Ibrance boosts effect of HIF2A inhibition in renal cancer

DISEASE CATEGORY: Cancer INDICATION: Renal cancer A team led by William Kaelin Jr., a winner of this year's Nobel Prize in Physiology or Medicine, showed that Ibrance palbociclib, which inhibits CDK4 and CDK6, could enhance...
BC Extra | Sep 14, 2019
Company News

Sept. 13 Company Quick Takes: FDA issues warning on CDK4/6 drugs; plus Castle Creek to buy Fibrocell and Eidos rebuffs BridgeBio

FDA warns of lung inflammation for CDK4/6 drugs  FDA issued a warning Friday that marketed CDK4/6 breast cancer drugs have been associated with a severe but rare risk of lung inflammation. In a review of...
BC Extra | Aug 29, 2019
Preclinical News

Aug. 29 Preclinical Quick Takes: New targets for leukemia from Calico and stroke from Gero; predictors of checkpoint inhibitor response and more

Calico finds new target for sensitizing leukemia to NK cells  Calico Life Sciences LLC (South San Francisco, Calif.) showed in an eLife paper that blocking DCAF15, an adaptor for E3 ubiquitin ligase substrates, could boost...
BC Innovations | Aug 29, 2019
Distillery Therapeutics

Boosting cancer sensitivity to CDK4, CDK6 inhibitors by inhibiting the PRMT5-MDM4 axis

DISEASE CATEGORY: Cancer INDICATION: Melanoma; breast cancer; esophageal cancer; pancreatic cancer Inhibiting the PRMT5-MDM4 axis could increase the sensitivity of melanoma and other cancers to the dual CDK4/CDK6 inhibitor Ibrance palbociclib. In five human melanoma...
BC Innovations | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

DISEASE CATEGORY: Cancer INDICATION: Lung cancer, pancreatic cancer UCSF’s Kevan Shokat and colleagues have identified two sets of genes for which inhibition could improve the efficacy of KRAS G12C inhibitors. Through a CRISPR-based screen in...
Items per page:
1 - 10 of 138